Lipidomic Profile Revealed the Association of Plasma Lysophosphatidylcholines with Adolescent Obesity
Table 2
Summary of all significant variable importance in the projection (VIP)a values identified in the partial least squares discriminant analysis (PLS-DA).
O (50) vs. N (50)
ON (n = 25) vs. NN (n = 25)
OA (n = 25) vs. NA (n = 25)
VIP > 1
VIP > 1
VIP > 1
CE16:0
1.35
1.06
2.05
CE16:2
1.46
1.06
1.95
CE17:1
1.34
1.05
2.07
CE18:0
1.05
1.42
1.22
CE20:2
1.71
1.2
2.03
CE20:3
1.75
1.04
2.09
CE20:4
1.18
1.15
1.45
CE20:5
1.44
1.07
1.63
CE22:6
1.15
1.37
1.13
dhCer20:0
1.42
1.78
1.2
LPC18:1
2.33
2.22
1.59
LPC18:2
2.21
2.21
1.44
LPC20:0
1.94
1.79
1.32
LPC20:1
2.01
1.62
1.5
LPC20:2
1.91
1.8
1.18
LPC26:0
1.57
1.68
1.05
oddPC31:1
1.17
1.41
1.13
PC (18:2/20:4)
1.23
1.31
1.04
PC36:1
1.18
1.15
1.58
PC38:3
1.49
1.21
1.77
PC40:6
1.25
1.23
1.2
PC40:8
1.42
1.22
1.28
PE (16:0/0:0)
1.67
1.84
1.19
PE (18:0/0:0)
1.57
1.71
1.25
PE (20:4/0:0)
1.76
1.36
1.58
PE (O-34:2)
1.48
1.13
1.27
aA significant VIP was defined as VIP > 1. N, normal-weight group; O, obese group; NN, normal weight with traditional normal clinical plasma lipid levels; NA, normal weight with traditional abnormal clinical plasma lipid levels; ON, obese with traditional normal clinical plasma lipid levels; OA, obese with traditional abnormal clinical plasma lipid levels.
